Next |
home / stock / epgny / epgny message board
Subject | By | Source | When |
---|---|---|---|
EPGNY: effective Dec. 30,2022 a one for 4 | Renee | investorshub | 12/29/2022 1:51:05 PM |
znewcar1: PGNY 27% v5,1M c26.13 f84,8M H27.49 gap up hit 24.4 dip to S@24.5 near the open then climb | znewcar1 | investorshangout | 05/13/2020 8:39:22 PM |
PoemStone: DGAP-News: Epigenomics AG / Key word(s): Miscellaneous Correction of the Corporate News | PoemStone | investorshangout | 03/18/2019 4:46:20 PM |
BLOCKBUSTER - otherwise no words ... | Steve1HD1 | investorshub | 04/15/2016 12:36:19 PM |
We are excited by the FDA's decision to | Steve1HD1 | investorshub | 04/14/2016 7:26:31 AM |
thinking about NASDAQ: | karibik | investorshub | 04/14/2016 5:12:47 AM |
NEWS OUT: Epigenomics receives FDA approval | karibik | investorshub | 04/13/2016 12:36:31 PM |
NEWS - FDA approved - Strong .... :-) | Steve1HD1 | investorshub | 04/13/2016 12:28:17 PM |
FDA first step approved | harry74nrw | investorshub | 03/26/2014 11:47:21 PM |
Bad news for exas?? | harry74nrw | investorshub | 03/21/2014 7:30:52 PM |
Target is85 $ | harry74nrw | investorshub | 03/20/2014 1:39:06 PM |
First coverage buy | harry74nrw | investorshub | 03/20/2014 1:00:13 PM |
GERMANY | wagner | investorshub | 03/20/2014 9:43:47 AM |
Starting to boil .... | harry74nrw | investorshub | 03/19/2014 4:05:20 PM |
Good position for fda | harry74nrw | investorshub | 03/17/2014 8:39:55 AM |
Well done | harry74nrw | investorshub | 03/16/2014 10:15:48 AM |
good news from ARG | harry74nrw | investorshub | 03/10/2014 9:39:21 AM |
FDA Panel to Meet About Epigenomics' PMA for | harry74nrw | investorshub | 03/05/2014 7:33:23 PM |
AGM 2014 Invitation | wagner | investorshub | 03/05/2014 3:10:18 PM |
DGAP-News Epigenomics AG: Clinical study conducted in the | wagner | investorshub | 03/05/2014 11:14:59 AM |
News, Short Squeeze, Breakout and More Instantly...
Epigenomics Ag S/Adr Company Name:
EPGNY Stock Symbol:
OTCMKTS Market:
Under the primary base case analysis, annual m SEPT9 screening resulted in more Quality-adjusted-life-years gained (QALYG), CRC cases averted and CRC deaths averted than both annual FIT screening and Cologuard ® every three years, albeit at a higher colonoscopy referral rate ...
Dover, Delaware--(Newsfile Corp. - June 17, 2020) - Encode Ideas, L.P. Initiates Research on Epigenomics AG (Xetra: ECX.DE) (FSE: ECX) (OTC: EPGNF). The full research publication is available here and available on our website at www.encodelp.com . A summary follows: Encode Ideas, L.P., a h...
- Adherence rates and screening intervals recognized as decisive elements of successful screening strategies - BERLIN, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), today reported on micro-simulation model results indicating th...